Melanoma - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 1479 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Melanoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Melanoma - Pipeline Review, H1 2016', provides an overview of the Melanoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Melanoma
- The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 12
Melanoma Overview 13
Therapeutics Development 14
Melanoma - Therapeutics under Development by Companies 16
Melanoma - Therapeutics under Investigation by Universities/Institutes 37
Melanoma - Pipeline Products Glance 41
Melanoma - Products under Development by Companies 45
Melanoma - Products under Investigation by Universities/Institutes 73
Melanoma - Companies Involved in Therapeutics Development 79
Melanoma - Therapeutics Assessment 318
Drug Profiles 395
Melanoma - Dormant Projects 1366
Melanoma - Discontinued Products 1407
Melanoma - Product Development Milestones 1412
Appendix 1425

List of Tables

Number of Products under Development for Melanoma, H1 2016 67
Number of Products under Development for Melanoma - Comparative Analysis, H1 2016 68
Number of Products under Development by Companies, H1 2016 70
Number of Products under Development by Companies, H1 2016 (Contd..1) 71
Number of Products under Development by Companies, H1 2016 (Contd..2) 72
Number of Products under Development by Companies, H1 2016 (Contd..3) 73
Number of Products under Development by Companies, H1 2016 (Contd..4) 74
Number of Products under Development by Companies, H1 2016 (Contd..5) 75
Number of Products under Development by Companies, H1 2016 (Contd..6) 76
Number of Products under Development by Companies, H1 2016 (Contd..7) 77
Number of Products under Development by Companies, H1 2016 (Contd..8) 78
Number of Products under Development by Companies, H1 2016 (Contd..9) 79
Number of Products under Development by Companies, H1 2016 (Contd..10) 80
Number of Products under Development by Companies, H1 2016 (Contd..11) 81
Number of Products under Development by Companies, H1 2016 (Contd..12) 82
Number of Products under Development by Companies, H1 2016 (Contd..13) 83
Number of Products under Development by Companies, H1 2016 (Contd..14) 84
Number of Products under Development by Companies, H1 2016 (Contd..15) 85
Number of Products under Development by Companies, H1 2016 (Contd..16) 86
Number of Products under Development by Companies, H1 2016 (Contd..17) 87
Number of Products under Development by Companies, H1 2016 (Contd..18) 88
Number of Products under Development by Companies, H1 2016 (Contd..19) 89
Number of Products under Investigation by Universities/Institutes, H1 2016 90
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 91
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 92
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 93
Comparative Analysis by Late Stage Development, H1 2016 94
Comparative Analysis by Clinical Stage Development, H1 2016 95
Comparative Analysis by Early Stage Development, H1 2016 96
Comparative Analysis by Unknown Stage Development, H1 2016 97
Products under Development by Companies, H1 2016 98
Products under Development by Companies, H1 2016 (Contd..1) 99
Products under Development by Companies, H1 2016 (Contd..2) 100
Products under Development by Companies, H1 2016 (Contd..3) 101
Products under Development by Companies, H1 2016 (Contd..4) 102
Products under Development by Companies, H1 2016 (Contd..5) 103
Products under Development by Companies, H1 2016 (Contd..6) 104
Products under Development by Companies, H1 2016 (Contd..7) 105
Products under Development by Companies, H1 2016 (Contd..8) 106
Products under Development by Companies, H1 2016 (Contd..9) 107
Products under Development by Companies, H1 2016 (Contd..10) 108
Products under Development by Companies, H1 2016 (Contd..11) 109
Products under Development by Companies, H1 2016 (Contd..12) 110
Products under Development by Companies, H1 2016 (Contd..13) 111
Products under Development by Companies, H1 2016 (Contd..14) 112
Products under Development by Companies, H1 2016 (Contd..15) 113
Products under Development by Companies, H1 2016 (Contd..16) 114
Products under Development by Companies, H1 2016 (Contd..17) 115
Products under Development by Companies, H1 2016 (Contd..18) 116
Products under Development by Companies, H1 2016 (Contd..19) 117
Products under Development by Companies, H1 2016 (Contd..20) 118
Products under Development by Companies, H1 2016 (Contd..21) 119
Products under Development by Companies, H1 2016 (Contd..22) 120
Products under Development by Companies, H1 2016 (Contd..23) 121
Products under Development by Companies, H1 2016 (Contd..24) 122
Products under Development by Companies, H1 2016 (Contd..25) 123
Products under Development by Companies, H1 2016 (Contd..26) 124
Products under Development by Companies, H1 2016 (Contd..27) 125
Products under Investigation by Universities/Institutes, H1 2016 126
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 127
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 128
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 129
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 130
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 131
Melanoma - Pipeline by 4SC AG, H1 2016 132
Melanoma - Pipeline by AB Science SA, H1 2016 133
Melanoma - Pipeline by AbbVie Inc., H1 2016 134
Melanoma - Pipeline by ACF Pharmaceuticals, LLC, H1 2016 135
Melanoma - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 136
Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 137
Melanoma - Pipeline by Adicet Bio, Inc., H1 2016 138
Melanoma - Pipeline by Aduro BioTech, Inc., H1 2016 139
Melanoma - Pipeline by Advaxis, Inc., H1 2016 140
Melanoma - Pipeline by Aeterna Zentaris Inc., H1 2016 141
Melanoma - Pipeline by Affichem SA, H1 2016 142
Melanoma - Pipeline by Agalimmune Ltd, H1 2016 143
Melanoma - Pipeline by Agenus, Inc., H1 2016 144
Melanoma - Pipeline by Agilvax, Inc., H1 2016 145
Melanoma - Pipeline by AGV Discovery, SAS, H1 2016 146
Melanoma - Pipeline by AIMM Therapeutics B.V., H1 2016 147
Melanoma - Pipeline by Alethia Biotherapeutics Inc., H1 2016 148
Melanoma - Pipeline by Altor BioScience Corporation, H1 2016 149
Melanoma - Pipeline by Amgen Inc., H1 2016 150
Melanoma - Pipeline by Anavex Life Sciences Corp., H1 2016 151
Melanoma - Pipeline by Angimmune LLC, H1 2016 152
Melanoma - Pipeline by Antibe Therapeutics, Inc., H1 2016 153
Melanoma - Pipeline by Antigen Express, Inc., H1 2016 154
Melanoma - Pipeline by APEIRON Biologics AG, H1 2016 155
Melanoma - Pipeline by Apexigen, Inc., H1 2016 156
Melanoma - Pipeline by Aphios Corporation, H1 2016 157
Melanoma - Pipeline by APO-T B.V., H1 2016 158
Melanoma - Pipeline by Apogenix GmbH, H1 2016 159
Melanoma - Pipeline by Aposense Ltd., H1 2016 160
Melanoma - Pipeline by Aptose Biosciences Inc., H1 2016 161
Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 162
Melanoma - Pipeline by Array BioPharma Inc., H1 2016 163
Melanoma - Pipeline by Asana BioSciences, LLC, H1 2016 164
Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 165
Melanoma - Pipeline by AstraZeneca Plc, H1 2016 166
Melanoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 167
Melanoma - Pipeline by Azaya Therapeutics, Inc., H1 2016 168
Melanoma - Pipeline by Basilea Pharmaceutica AG, H1 2016 169
Melanoma - Pipeline by Batu Biologics, Inc., H1 2016 170
Melanoma - Pipeline by Bayer AG, H1 2016 171
Melanoma - Pipeline by BeiGene, Ltd., H1 2016 172
Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 173
Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 174
Melanoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 175
Melanoma - Pipeline by BioApex, s.r.o., H1 2016 176
Melanoma - Pipeline by BIOCAD, H1 2016 177
Melanoma - Pipeline by Biogazelle, H1 2016 178
Melanoma - Pipeline by Biogenomics Limited, H1 2016 179
Melanoma - Pipeline by BioLineRx, Ltd., H1 2016 180
Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2016 181
Melanoma - Pipeline by Bionomics Limited, H1 2016 182
Melanoma - Pipeline by BioNTech AG, H1 2016 183
Melanoma - Pipeline by Bioo Therapeutics, H1 2016 184
Melanoma - Pipeline by Biovista Inc., H1 2016 185
Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 186
Melanoma - Pipeline by Boston Biomedical, Inc., H1 2016 187
Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 188
Melanoma - Pipeline by Calithera Biosciences, Inc., H1 2016 189
Melanoma - Pipeline by Can-Fite BioPharma Ltd., H1 2016 190
Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2016 191
Melanoma - Pipeline by Cellceutix Corporation, H1 2016 192
Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 193
Melanoma - Pipeline by Celprogen, Inc., H1 2016 194
Melanoma - Pipeline by Celyad SA, H1 2016 195
Melanoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016 196
Melanoma - Pipeline by Cipher Pharmaceuticals Inc., H1 2016 19